MAGNESIUM OROTATE IN COMPLEX THERAPY OF METABOLIC DISORDERS IN PATIENTS WITH GOUT

Abstract

In 25–90 % patients with gout we detect metabolic syndrome (MS), and on the contrary – in patients with MS significantly increases the risk of gout and hyperuricemia (HU). About 40–50 % of MS cases are combined with magnesium deficiency. Comprehensive treatment of MS with the addition of magnesium drugs leads to more effective normalization of lipid and glycemic profiles, lowering blood pressure, prevention of atherosclerosis. The aim of the study – determining the prevalence of MS and diabetes mellitus in patients with gout and the possibility of its correction. Materials and Methods. We examined 45 patients with gout in Rheumatology Department of Ternopil University hospital. Patients were divided into two groups: I group (n=23) – received standard hypouricemic treatment by Allopurinol, NSAIDs, and magnesium orotate in a daily dose of 1500 mg. Patients of group II (n=22), control group, received only Allopurinol and NSAIDs. Results and Discussion. Dynamic monitoring of the main clinical and laboratory parameters indicated that patients who received the combined therapy with magnesium orotate showed significantly better outcomes than the control group. Conclusion. Magnesium orotate can be recommended in gout treatment for metabolic disorders.

Keywords

• подагра
• метаболічний синдром
• магнію оротат.